Home / 0HB0.L / Company Profile

Agios Pharmaceuticals Inc

0HB0.L | Healthcare | LSE
🌐 Website 📊 Reports 📈 Financials
$43.17
+0.33 (+0.78%)

Key Metrics

Market Cap
$2.51B
P/E Ratio
-6.72
EPS
$-6.43
Beta
N/A
Dividend Yield
N/A
ROE
43.31%
Current Ratio
14.48

Company Information

Industry
Medical Pharmaceuticals

About Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc a biopharmaceutical company engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology The company offers PYRUKYND mitapivat an activator of both wildtype and a variety of mutant pyruvate kinase PK enzymes for the treatment of hemolytic anemias and AG946 that is in Phase I clinical study for treating hemolytic anemias and other indications Agios Pharmaceuticals Inc was incorporated in 2007 and is headquartered in Cambridge Massachusetts

Recent Earnings Surprises

Date Actual EPS Estimated EPS Surprise
2025-10-30 $-1.78 $-1.90 +-6.1%
2025-07-31 $-1.93 $-1.81 7.0%
2025-05-01 $-1.55 $-1.77 +-12.5%
2025-02-13 $-1.69 $-1.69 +-0.1%

Financial Ratios (TTM)

Gross Margin
-99.50%
Operating Margin
-1,129.13%
Net Margin
1,590.42%
ROA
44.19%
Price to Book
1.83
Price to Sales
61.45